FAYETTEVILLE, Ark., March 5, 2026 /PRNewswire/ -- HTA and Venture Atlas Labs announced a new commercial and clinical acceleration program that connects international health technology companies with ...

Abstract: The increasing interest from research agencies, governments, and universities in understanding research funding and prioritising research efforts has highlighted the need for reliable and ...

Hello, and thank you for standing by. At this time, I would like to welcome everyone to the CareDx Investor Webinar Call. [Operator Instructions] I would now like to turn the conference over to ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif., February 12, 2026 ...

Dr. Mazzone and colleagues report on a cell-free DNA fragmentome assay (DELFIscore) for the classification of lung cancer (1). We have concerns and recommendations. Study participants were enrolled ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...

Objectives This study describes the prototype testing and clinical validation of the Fit-Frailty App, a fully guided, interactive mobile health (mHealth) app to assess frailty and sarcopenia. This ...

Abstract: Objective: Neonatal late-onset sepsis (LOS) is a life-threatening condition in preterm infants in neonatal intensive care units (NICUs), with early detection being crucial for improving ...

Health care leaders may want to keep a closer eye on clinical validation for artificial intelligence (AI)-enabled medical devices (AIMDs), based on a recent JAMA Health Forum study. The study examined ...